| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
* Department of Radiochemistry and Radiopharmacology, German Cancer Research Center, Heidelberg, Germany;
Division of Rheumatology and Clinical Immunology, Department of Internal Medicine I, University of Regensburg, Germany;
Cell Biophysics/Cell Biology Program, European Molecular Biology Laboratory, Heidelberg, Germany;
Department of Hematology, Oncology and Rheumatology, Clinic of Internal Medicine V, and
¶
First Department of Medicine, Faculty of Clinical Medicine, Mannheim, University of Heidelberg, Heidelberg, Germany; and
||
World Health Organization Collaborating Center for Molecular Biology and Novel Therapeutic Strategies for Rheumatic Diseases, University of Zurich, Zurich, Switzerland
We reported recently that albumin is a suitable drug carrier for targeted delivery of methotrexate (MTX) to tumors. Due to pathophysiological conditions in neoplastic tissue, high amounts of albumin accumulate in tumors and are metabolized by malignant cells. MTX, covalently coupled to human serum albumin (MTX-HSA) for cancer treatment, is currently being evaluated in phase II clinical trials. Because synovium of patients with rheumatoid arthritis (RA) shares various features observed also in tumors, albumin-based drug targeting of inflamed joints might be an attractive therapeutic approach. Therefore, the pharmacokinetics of albumin and MTX in a mouse model of arthritis was examined. Additionally, uptake of albumin by synovial fibroblasts of RA patients and the efficacy of MTX and MTX-HSA in arthritic mice were studied. The results show that when compared with MTX, significantly higher amounts of albumin accumulate in inflamed paws, and significantly lower amounts of albumin are found in the liver and the kidneys. The protein is metabolized by human synovial fibroblasts in vitro and in vivo. MTX-HSA was significantly more effective in suppression of the onset of arthritis in mice than was MTX. In conclusion, albumin appears to be a suitable drug carrier in RA, most likely due to effects on synovial fibroblasts, which might increase therapeutic efficacy and reduce side effects of MTX.
Related articles in The JI:
This article has been cited by other articles:
|
|
 |
|
  C. Norez, M. Pasetto, M. C. Dechecchi, E. Barison, C. Anselmi, A. Tamanini, F. Quiri, L. Cattel, P. Rizzotti, F. Dosio, et al. Chemical conjugation of {Delta}F508-CFTR corrector deoxyspergualin to transporter human serum albumin enhances its ability to rescue Cl- channel functions Am J Physiol Lung Cell Mol Physiol, August 1, 2008; 295(2): L336 - L347. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C Fiehn, F Kratz, G Sass, U Muller-Ladner, and E Neumann Targeted drug delivery by in vivo coupling to endogenous albumin: an albumin-binding prodrug of methotrexate (MTX) is better than MTX in the treatment of murine collagen-induced arthritis Ann Rheum Dis, August 1, 2008; 67(8): 1188 - 1191. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. J. Holt, A. Basran, K. Jones, J. Chorlton, L. S. Jespers, N. D. Brewis, and I. M. Tomlinson Anti-serum albumin domain antibodies for extending the half-lives of short lived drugs Protein Eng. Des. Sel., May 1, 2008; 21(5): 283 - 288. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Yanaba, Y. Hamaguchi, G. M. Venturi, D. A. Steeber, E. W. St. Clair, and T. F. Tedder B Cell Depletion Delays Collagen-Induced Arthritis in Mice: Arthritis Induction Requires Synergy between Humoral and Cell-Mediated Immunity J. Immunol., July 15, 2007; 179(2): 1369 - 1380. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Elewaut Right on target: coupling methotrexate to albumin to treat rheumatoid arthritis Rheumatology, September 1, 2004; 43(9): 1067 - 1068. [Full Text] [PDF]
|
|
|
|
|
|
C. Fiehn, U. Muller-Ladner, S. Gay, S. Krienke, S. Freudenberg-Konrad, J. Funk, A. D. Ho, H. Sinn, and A. Wunder Albumin-coupled methotrexate (MTX-HSA) is a new anti-arthritic drug which acts synergistically to MTX Rheumatology, September 1, 2004; 43(9): 1097 - 1105. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C Fiehn, E Neumann, A Wunder, S Krienke, S Gay, and U Muller-Ladner Methotrexate (MTX) and albumin coupled with MTX (MTX-HSA) suppress synovial fibroblast invasion and cartilage degradation in vivo Ann Rheum Dis, July 1, 2004; 63(7): 884 - 886. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Robin Goodfellow Rheumatology, September 1, 2003; 42(9): 1131 - 1131. [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
